- Details
- In this conversation with Alicia Morgans, Rafee Talukder and Petros Grivas share data that investigates comparing the outcomes in patients who received prior intravesical BCG, and those patients who progressed and then required immune checkpoint inhibitors, to see if prior BCG therapy had an effect on the response on immune checkpoint inhibitors. Their hypothesis was, that patients who received BC...
|
- Details
- Scott Tagawa joins Sam Chang to highlight the key topics of his discussion at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022. Dr. Tagawa provided a clinical perspective on antibody-drug conjugates in the treatment of urothelial carcinoma. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourin...
|
- Details
- Alicia Morgans is joined by Simon Crabb to discuss the analysis he presented at 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium regarding the rucaparib arm in the ATLANTIS trial among patients with metastatic urothelial carcinoma (mUC). ATLANTIS is a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following c...
|
- Details
- Sam Chang is joined by Deborah Kaye to discuss the "best papers" in urothelial carcinoma that she highlighted for her presentation at the GU ASCO 2022 Annual Meeting. She highlights four papers on urothelial carcinoma that she selected based on their clinical relevance and how they have a direct impact on bladder cancer patients today. Biographies: Deborah Kaye, MD, MS, Urologic Oncologist, Assist...
|
- Details
- At the 2022 ASCO GU meeting, Stephen Boorjian chaired a rapid abstract session in urothelial carcinoma focusing on three broad topics in advanced urothelial cancer. One abstract covers the role of neoadjuvant chemotherapy with gemcitabine and cisplatin, for patients with upper tract urothelial carcinoma. One abstract covers maintenance therapy with a checkpoint inhibitor, for patients who've not e...
|
- Details
- In this conversation with Sam Chang, Tracy Rose shares highlights from her GU ASCO 2022 presentation on novel therapies in bladder cancer and their toxicities, discussing the future of adjuvant and neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC). Biographies: Tracy L. Rose, MD, Assistant Professor of Medicine, Division of Oncology, The University of North Carolina at Ch...
|
- Details
- Yohann Loriot joins Sam Chang to discuss the results of the LEAP-011 trial which was designed to compare first-line pembrolizumab and lenvatinib to pembrolizumab monotherapy as first-line treatment of patients with advanced urothelial cancer (aUC) who are cisplatin-ineligible with PD-L1–positive tumors or are ineligible to receive platinum-based chemotherapy. Biographies: Yohann Loriot, PhD, MD, G...
|
- Details
- Dimitrios Makrakis joins Alicia Morgans and Petros Grivas in a discussion on a BJU International publication titled The Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer looking at a data set trying to understand the important potential interaction between exposure to checkpoint inhibitors and local therapy for patients at the time of diagnosis ass...
|
- Details
- Alicia Morgans is joined by Elizabeth Plimack to discuss the importance of the Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program. BCAN is the Bladder Cancer Advocacy Network which started as a small group of urology-based advocates and has grown to "the" organization for bladder cancer advocacy. The Young Investigator Award program strives to grow the science in bladder can...
|
- Details
- In this 2021 LUGPA presentation, Noah Hahn presents " Biomarkers and Next-Generation Sequencing in Advanced Bladder Cancer Patients" . Dr. Hahn discusses the differences in prognostic biomarkers and predictive biomarkers before discussing PD-L1 on the immunohistochemistry side, sequencing biomarkers, tumor mutational burden, and microsatellite instability or mismatch repair deficient tumors. Biogr...
|
